News articles about Globus Medical (NYSE:GMED) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Globus Medical earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media headlines about the medical device company an impact score of 45.5641387750545 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

GMED has been the subject of several recent research reports. Zacks Investment Research lowered shares of Globus Medical from a “buy” rating to a “hold” rating in a report on Friday, May 12th. Barclays PLC restated a “sell” rating and issued a $30.00 price target on shares of Globus Medical in a report on Monday, May 15th. Canaccord Genuity set a $37.00 price target on shares of Globus Medical and gave the company a “buy” rating in a report on Thursday, May 18th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Globus Medical in a report on Thursday, May 18th. Finally, BidaskClub upgraded shares of Globus Medical from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 22nd. Three analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $30.43.

Globus Medical (NYSE GMED) opened at 30.32 on Tuesday. The company has a market cap of $2.92 billion, a price-to-earnings ratio of 27.32 and a beta of 0.60. The company’s 50 day moving average is $30.50 and its 200 day moving average is $30.49. Globus Medical has a 1-year low of $19.25 and a 1-year high of $34.03.

Globus Medical (NYSE:GMED) last issued its earnings results on Wednesday, August 2nd. The medical device company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.02. The firm had revenue of $152.39 million for the quarter, compared to analysts’ expectations of $150.94 million. Globus Medical had a net margin of 18.12% and a return on equity of 13.99%. The firm’s revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.29 earnings per share. Equities research analysts forecast that Globus Medical will post $1.27 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/05/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-globus-medical-gmed-share-price.html.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Insider Buying and Selling by Quarter for Globus Medical (NYSE:GMED)

Receive News & Stock Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related stocks with our FREE daily email newsletter.